{
  "url": "https://openlegislation.uk/misuse-of-drugs-designation-amendment-no-2-england-wales-and-scotland-order-2017/note",
  "json_url": "https://openlegislation.uk/misuse-of-drugs-designation-amendment-no-2-england-wales-and-scotland-order-2017/note.json",
  "legislation": "uksi/2017/1118",
  "legislation_title": "The Misuse of Drugs (Designation) (Amendment) (No. 2) (England, Wales and Scotland) Order 2017",
  "legislation_url": "https://openlegislation.uk/misuse-of-drugs-designation-amendment-no-2-england-wales-and-scotland-order-2017",
  "path": "note",
  "kind": "note",
  "number": null,
  "heading": "Explanatory note",
  "text": "(This note is not part of the Order)\nSection 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 by inserting the drug known as methiopropamine or MPA into Part 1 of the Schedule to that Order.\nA full impact assessment of the effect that this instrument will have on the costs of business and the voluntary sector is available and is published with the Explanatory Memorandum alongside the instrument on www.legislation.gov.uk.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2017/1118/note",
    "retrieved_at": "2026-10-28T23:06:18.277091+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}